Print Page   |   Sign In   |   Register
Companies: Aethlon Medical, Inc (AEMD)

 

Company Profile
Image result for aethlon medical

Catalyst Research Article-Black Death Nov-17 Click Here

*Premium Profile-Catalyst Management Research Group Click Here

Description

Aethlon Medical is a San Diego, California based developer of immunotherapeutic technologies designed to mitigate the impact of infectious disease as well as cancer in humans.  The Company currently supports two distinct efforts in the medical technology space, each with opportunities to potentially address multiple large and critical health issues.  Aethlon was formed in formed in March 1999. 

Aethlon’s initial and “lead” product is a device which they refer to as a Hemopurifier®.  The Hemopurifier® is a blood filter that is applied much like dialysis.  Per the Company’s description, the device “eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study”. 

To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).  In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare." 

Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats. These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.  Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919.  In vitro studies of other viral threats are ongoing.  

Aethlon has also demonstrated that the Hemopurifier captures the bacteria toxins lipopolysaccharide (LPS) and lipoteichoic acid (LTA).  These studies were conducted under a contract with the Defense Advanced Research Projects Agency (DARPA) related to the treatment of sepsis.

In addition to its flagship Hemopurifier technology, Aethlon is also a majority shareholder in Exosome Sciences, Inc.  Exosome is focused on “the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. In preliminary studies, Exosome has demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection”.  In addition, the Company is developing biomarkers to detect Chronic Traumatic Encephalopathy (CTE) in living individuals. CTE was most recently associated with brain trauma issues impacting NFL players. 

Contact Information

  • 9635 GRANITE RIDGE DRIVE
  • SUITE 100
  • SAN DIEGO, CA 92123

 

Financial Reporting/Disclosure

Reporting Status U.S. Reporting: SEC Reporting
Latest Report Jun 30, 2016 10-Q
CIK 0000882291
Fiscal Year End 3/31
OTC Marketplace Not Available

Profile Data

SIC - Industry Classification Not Available
Business Status Development Stage Company a/o Jul 28, 2011
Incorporated In: NV, USA
Year of Inc. Not Available
Employees 8 a/o May 13, 2015

Company Notes

  • Formerly=Bishop Equities, Inc. until 3-00

Service Providers

Accounting/Auditing Firm
Squar, Milner, Peterson, Miranda & Williamson, LLP
3655 Nobel Drive
Suite 450
San Diego, CA, 92122
United States

Legal Counsel
Raines Feldman LLP
9720 Wishire Blvd.
Beverly Hills, CA, 90212
United States

Investor Relations Firm
Not Available

 
Community Search
Sign In